Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol CTCFL contributors: mct/pgu - updated : 13-04-2020
HGNC name CCCTC-binding factor (zinc finger protein)-like
HGNC id 16234
TRANSCRIPTS type messenger
text varying promoter usage driving multiple transcripts could influence many aspects of epigenetic reprogramming in normal development and in tumorigenesis
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
12 - 3493 - 663 - 2007 17957795
also called variant 1
11 - 3601 - 663 - 2007 17957795
  • variant A1
  • having promoter A preferentially used upon activation of BORIS during tumorigenesis
  • - - 3701 - 663 - 2007 17957795
  • having promoter A preferentially used upon activation of BORIS during tumorigenesis
  • 10 - 3897 - 613 - 2007 17957795
  • variant A3
  • having promoter A preferentially used upon activation of BORIS during tumorigenesis
  • 10 - 4073 - 663 - 2007 17957795
  • variant C1
  • having promoter C preferentially used upon activation of BORIS during tumorigenesis
  • 11 - 3598 - 662 - 2007 17957795
    10 - 3002 - 573 - 2007 17957795
    10 - 2955 - 627 - 2007 17957795
    5 - 1513 - 404 - 2007 17957795
    10 - 2295 - 422 - 2007 17957795
    8 - 2168 - 299 - 2007 17957795
    12 - 2499 - 700 - 2007 17957795
    10 - 2288 - 460 - 2007 17957795
    10 - 2077 - 403 - 2007 17957795
    4 - 1985 - 404 - 2007 17957795
    Type restricted
       expressed in (based on citations)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Reproductivemale systemtestis    Homo sapiens
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Blood / hematopoieticbone marrow   
    SystemCellPubmedSpeciesStageRna symbol
    Reproductivegerm cell
    cell lineage
    cell lines
    at STAGE
  • eleven zinc fingers flanked by polypeptides of unknown structure and function, an 11ZF domain that is highly similar to the 11ZF domain of CTCF
  • unstructured terminal segments of CTCF and CTCFL that could recruit different binding partners to chromosomes
    intraspecies paralog to CTCF
  • cancer testis antigen (CTA) family
  • CTCF zinc-finger protein family
  • CATEGORY regulatory , tumor suppressor
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,nucleus,nucleoplasm,nuclear bodies
  • cytoplasm of spermatocytes
  • is confined to the nucleolus and other euchromatin domains, but also localises to interphase centrosomes suggesting a role in the cell cycle
  • in the nucleus, is particularly enriched in the nucleolus, a crucial compartment for ribosomal RNA and RNA metabolism
  • basic FUNCTION
  • involved in different aspects of gene regulation including promoter activation or repression, hormone-responsive gene silencing, methylation- dependent chromatin insulation, and genomic imprinting
  • possible involvement in the establishment, progression and maintenance of breast tumours
  • has acquired testis-specific functions in mammalian organisms
  • DNA-binding factor that regulates the transcriptional program of mammalian male germ cells
  • plays important physiological functions in progression of spermatogenesis by regulating expression of a testis-specific splicing variant of cerebroside sulfotransferase
  • directly involved in activation of PRSS50 expression by binding to the promoter region
  • potential role for BORIS in coordinating S phase events with mitosis
  • is likely involved in gene expression at both the transcriptional and post-transcriptional levels
  • is associated with cancer stem cell-enriched populations of several epithelial tumor cells and the different phenotypes depend on the origin of tumor cells
  • CTCFL is enriched at transcriptional start sites and regions bound by transcription factors
  • plays crucial roles during spermatogenesis and production of sperm
  • is involved in the regulation of cancer stem cells (CSCs) cellular and molecular features such as self-renewal, chemo-resistance, tumorigenicity, sphere-forming ability, and migration capacity
  • DNA binding protein which is involved in tumorigenesis
  • pro-invasive role for CTCFL in melanoma via transcriptional reprogramming
  • CELLULAR PROCESS nucleotide, transcription, regulation
    a component
    DNA binding
    small molecule metal binding,
  • Zn2+
  • protein
  • CTCFL positively regulates MAGEA2, MAGEA3, MAGEA4 by binding and inducing a shift to a more open chromatin conformation with promoter demethylation for MAGEA3 or independent of promoter demethylation in case of MAGEA2 and MAGEA4
  • directly responsible for the transcriptional activation of PRSS50
  • in cancer cells, key role for CTCFL as the main mediator of transcriptional deregulation of NOTCH3
  • CTCFL and Sp1 have opposite effects on the regulation of MAGEA1 gene expression
  • interaction between MAGEA1 and CTCF, which is required for the binding of MAGEA1 to the CTCFL promoter and is critical for the recruitment of DNMT3A
  • binds near the promoter of TFGB1, a well-recognized factor involved in the transition towards an invasive state, which coincided with increased expression of TGFB1
  • cell & other
    inhibited by MAGEA1 that inhibits the expression of CTCL via increased promoter methylation
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in juvenile angiofibroma in the posterior nasal cavity of adolescent males
    tumoral     --other  
    aberrantly expressed in melanoma
    tumoral     --over  
    in high-grade epithelial ovarian cancer
    Variant & Polymorphism
    Candidate gene
  • candidate protein for the elusive epigenetic reprogramming factor acting in the male germ line
  • potential practical applications as a molecular biomarker of breast cancer
  • Marker
  • aberrant CTCFL hypomethylation is a promising biomarker for the prognosis of hepatocellular carcinoma
  • Therapy target
  • has the potential to be used as a prognostic biomarker and to yield novel drug targets among the genes CTCFL controls in serous ovarian cancer (SOC) patients
  • Mice homozygous for the null allele had a defect in spermatogenesis that resulted in small testes associated with increased cell death